TP53 and neoplasm: Particularly, the ErbB receptor-mediated Ras-MAPK and PI3K/AKT pathway, and the p53-mediated DNA damage-response pathway, are modeled and integrated to predict the kill probability of tumor cells under specific drug combinations or radiation treatment and patient-specific miRNA expression levels.